The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

Diabetes

Volumn 62, Issue 9, 2013, Pages 3275-3281

  'T Hart, Leen M ^a   Fritsche, Andreas ^b   Nijpels, Giel ^c   Van Leeuwen, Nienke ^a   Donnelly, Louise A ^d   Dekker, Jacqueline M ^c   Alssema, Marjan ^c   Fadista, Joao ^e   Carlotti, Françoise ^a   Gjesing, Anette P ^f   Palmer, Colin N A ^d   Van Haeften, Timon W ^g   Herzberg Schäfer, Silke A ^b   Simonis Bik, Annemarie M C ^c   Houwing Duistermaat, Jeanine J ^a   Helmer, Quinta ^a   Deelen, Joris ^a   Guigas, Bruno ^a   Hansen, Torben ^f,h   Machicao, Fausto ^b   Willemsen, Gonneke ⁱ   Heine, Robert J ^c,j   Kramer, Mark H H ^c   Holst, Jens J ^f   De Koning, Eelco J P ^a,k   Häring, Hans Ulrich ^b   Pedersen, Oluf ^f,l   Groop, Leif ^e   De Geus, Eco J C ^c,i   Slagboom, P Eline ^a,m   Boomsma, Dorret I ⁱ   Eekhoff, Elisabeth M W ^c   Pearson, Ewan R ^d   Diamant, Michaela ^c   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f Capital Region   (Denmark)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

ⁱ VU UNIVERSITY AMSTERDAM   (Netherlands)

^j ELI LILLY AND COMPANY   (United States)

^k HUBRECHT INSTITUTE   (Netherlands)

^l AARHUS UNIVERSITY   (Denmark)

^m Netherlands Consortium for Healthy Ageing   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; CHYMOTRYPSINOGEN; CHYMOTRYPSINOGEN B1; CHYMOTRYPSINOGEN B2; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CHYMOTRYPSIN B; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INSULIN;

ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE PREDISPOSITION; ENZYME ACTIVITY; GENE LOCUS; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTAKE; QUANTITATIVE TRAIT LOCUS; SIGNAL TRANSDUCTION; ADULT; AGED; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENETICS; GENOTYPE; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; CHYMOTRYPSIN; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GENOTYPE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; MIDDLE AGED; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 84885215197     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0227     Document Type: Article

References (34)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroen-terology 2007;132:2131-2157
2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87: 1409-1439
3. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-2952
4. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124(Suppl.):S3- S18
5. Müssig K, Staiger H, Machicao F, Häring HU, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 2010;53: 2289-2297
6. Simonis-Bik AM, Eekhoff EM, de Moor MH, et al. Genetic influences on the insulin response of the beta cell to different secretagogues. Diabetologia 2009;52:2570-2577
7. 't Hart LM, Simonis-Bik AM, Nijpels G, et al. Combined risk allele score of eight type 2 diabetes genes is associated with reduced first-phase glucose-stimulated insulin secretion during hyperglycemic clamps. Diabetes 2010; 59: 287-292
8. Fritsche A, Madaus A, Renn W, et al. The prevalent Gly1057Asp polymorphism in the insulin receptor substrate-2 gene is not associated with impaired insulin secretion. J Clin Endocrinol Metab 2001;86:4822-4825
9. Zavrelova H, Hoekstra T, Alssema M, et al. Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the Diabetes Care System West-Friesland, the Netherlands. Diabetes Care 2011;34:867-872
10. Morris AD, Boyle DIR, MacAlpine R, et al.; DARTS/MEMO Collaboration. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. BMJ 1997;315:524-528
11. Fritsche A, Stefan N, Hardt E, Schützenauer S, Häring H, Stumvoll M. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility. Eur J Clin Invest 2000;30:411-418
12. Voight BF, Kang HM, Ding J, et al. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet 2012;8:e1002793
13. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44:981-990
14. Zhou K, Bellenguez C, Spencer CC, et al.; GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group; Wellcome Trust Case Control Consortium 2; MAGIC investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011;43:117-120
15. Taneera J, Lang S, Sharma A, et al. A systems genetics approach identifies genes and pathways for type 2 diabetes in human islets. Cell Metab 2012; 16:122-134
16. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105-1111
17. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol 2010;11:R25
18. Kaspar P, Moller G, Wahlefeld A, Staehler F. A new photometric method for the determination of chymotrypsin in stool. Fresenius Z Anal Chem 1982;311:391-392
19. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010;26:2336-2337
20. Barrett JC, Clayton DG, Concannon P, et al.; Type 1 Diabetes Genetics Consortium. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703-707
21. Tinoco AD, Tagore DM, Saghatelian A. Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J Am Chem Soc 2010;132:3819-3830
22. Grundberg E, Small KS, Hedman AK, et al.; Multiple Tissue Human Expression Resource (MuTHER) Consortium. Mapping cis-and trans-regulatory effects across multiple tissues in twins. Nat Genet 2012;44: 1084-1089
23. Boyle AP, Hong EL, Hariharan M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012;22: 1790-1797
24. Mercader JM, Puiggros M, Segrè AV, et al.; DIAGRAM Consortium; MITIN Consortium. Identification of novel type 2 diabetes candidate genes involved in the crosstalk between the mitochondrial and the insulin signaling systems. PLoS Genet 2012;8:e1003046
25. Eizirik DL, Sammeth M, Bouckenooghe T, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet 2012;8:e1002552
26. Pournaras DJ, Aasheim ET, Bueter M, et al. Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. Surg Obes Relat Dis 2012;8:371-374
27. Schwartz JG, Guan D, Green GM, Phillips WT. Treatment with an oral proteinase inhibitor slows gastric emptying and acutely reduces glucose and insulin levels after a liquid meal in type II diabetic patients. Diabetes Care 1994;17:255-262
28. Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000;6:4684-4691
29. Villegas R, Gao YT, Yang G, et al. Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women's Health Study. Am J Clin Nutr 2008;87:162-167
30. Larger E, Philippe MF, Barbot-Trystram L, et al. Pancreatic exocrine function in patients with diabetes. Diabet Med 2012;29:1047-1054
31. Cure P, Pileggi A, Alejandro R. Exenatide and rare adverse events. N Engl J Med 2008;358:1969-1970; discussion 1971-1972
32. Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat? Diabetes 2012;61:986-988
33. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Gluca-gonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-539
34. PanScan Consortium; Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case-Control Consortium. PanScan, 2013. Available from http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/analysis.cgi?studyid=phs000206. v3.p2&pha=2889. Accessed 1 April 2013